A biotech firm in Sweden has announced that phase I testing of a drug to treat obesity has begun on humans. Karo Bio took over the project following the abandonment of Bristol-Myers Squibb last year.
The drug, known as KB2115, significantly lowered body fat in animals. The substance triggers the receptor in the thyroid, increasing the body’s consumption of energy. During Phase I, healthy but overweight humans will be involved.
Karo Bio’s CEO said: “We want to develop this into a drug. We could theoretically push this all the through to phase III if we choose a small and well defined patient group… we have a number of years ahead of us in clinical studies.”